Editorial Reflects Conservative Approach To Use Of Drug-Eluting Stents
This article was originally published in The Gray Sheet
Executive Summary
As apprehension over the use of drug-eluting stents grows, two cardiologists last week fired another salvo, asserting that the overuse of DES is placing too many patients in harm's way for little or no added benefit
You may also be interested in...
U.S. DES Use Will Stabilize At Already Lowered Rates, Physicians Suggest
Recommendations by an FDA advisory panel earlier this month will likely reinforce, but not amplify, already moderated usage patterns of drug-eluting stents in the U.S., doctors suggest
U.S. DES Use Will Stabilize At Already Lowered Rates, Physicians Suggest
Recommendations by an FDA advisory panel earlier this month will likely reinforce, but not amplify, already moderated usage patterns of drug-eluting stents in the U.S., doctors suggest
Thrombosis Risk In Taxus And Cypher Is Real, TCT Data Shows; Now What?
With a growing consensus coming out of last week's Transcatheter Cardiovascular Therapeutics meeting that first-generation drug-eluting stents (DES) are associated with an increased long-term risk of blood clots, cardiologists are grappling with how use of these blockbuster products might need to be modified